Toronto, Ontario – November 7, 2023 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company”), is pleased to announce that it has closed the previously announced acquisition (see press release dated October 27,...
Toronto, Ontario – July 18, 2023 – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), announced today that it has reached an agreement yesterday with PharmaTher Inc. (“PharmaTher”), a...
Toronto, Ontario – February 13, 2023 – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs,...
Toronto, Ontario – January 31, 2023) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and...
Completes clinical trial-scale production of cGMP Cepharanthine-2HCL drug substance Optimized manufacturing processes substantially increases drug product yield To initiate ICH-compliant stability, forced degradation and drug product manufacturing in support of IND...
PharmaDrug completes all necessary research on lead DMT-analogue to support filing of provisional patent describing novel therapeutic and delivery device for treatment of glaucoma in Q4, 2022 PharmaDrug extends contract with investigators at Johns Hopkins University...